The advancement of radiopharmaceuticals – radioactive compounds that can be used for diagnostic or therapeutic purposes – has created one of the most effective forms of precision medicine to date, giving patients and providers an attractive new option in an ever-growing list of cellular targets and indications.
Managing these trials presents challenges for sponsors due to the complexity of regulatory requirements in each country and the need for experienced, highly trained sites and close coordination of multiple stakeholders for the just-on-time dosing of patients.
PSI CRO is a Swiss-based clinical research organization running 40% of the industry’s pivotal radiopharm studies. In this webinar, Dylan Stoy, PSI’s Director of Therapeutic Strategy for radiopharmaceuticals, will discuss:
- Challenges in designing radiopharmaceutical trials
- The importance of site support
- Advancing your radiopharmaceutical product with strategic partnerships
**This webinar was originally presented in collaboration with Tonacea, a Chinese biotech industry group dedicated to novel drugs R&D, communication, and innovation.
Dylan Stoy, Therapeutic Strategy Director
Dylan Stoy, PSI’s Therapeutic Strategy Director, is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has over a decade of experience in all phases of research and has worked in radiopharmaceutical research for nine years, with research interests in targeted drug delivery systems and optimizing the conduct of studies. Dylan has overseen radiopharmaceutical research in various roles, including on-site research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.
Dylan and his team are devoted to making participation for sites and patients in complex radiopharmaceutical studies more attainable and ensuring that PSI teams are highly trained and equipped to handle any challenges your program might encounter. An integral part of the conceptualization and development of PSI’s Therapeutic Strategy Department, Dylan works closely with the core business units within PSI, overseeing research throughout the study lifecycle, providing strategic leadership to teams and collaborators (both internally and externally), and delivering corporate-wide training to make PSI a full-service CRO for radiopharmaceutical development.
